GLP-1 Cardiovascular

4 articles in this topic.

Complete Guides

GLP-1 Drugs and Heart Disease: Cardiovascular Trials

Seven major trials tested GLP-1 drugs for heart protection. What LEADER, SUSTAIN-6, SELECT, and other CVOTs found about heart attacks, strokes, and death.

19 min read|Mar 20, 2026

All Articles

GLP-1 Cardiovascular

GLP-1 Agonists and Atherosclerosis

GLP-1 receptor agonists reduce atherosclerotic cardiovascular events by 12-26% in major trials. Here is how they protect arteries at the cellular level.

13 min read|Mar 22, 2026

GLP-1 Cardiovascular

How GLP-1 Drugs Reduce Cardiovascular Inflammation

GLP-1 receptor agonists lower cardiovascular inflammation via NF-kB suppression, macrophage modulation, and epicardial fat changes. Here's the evidence.

14 min read|Mar 22, 2026

GLP-1 Cardiovascular

Do GLP-1 Agonists Lower Blood Pressure?

GLP-1 agonists reduce systolic blood pressure by 2-5 mmHg on average. Here is what meta-analyses, CVOTs, and mechanistic research reveal.

14 min read|Mar 21, 2026